Robert F. Kennedy Jr.'s nomination for US health secretary advances with crucial Republican support, despite controversy over ...

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of ...

Wall Street rebounds as tech stocks surge, with the S&P 500 up 0.5% amid easing trade tensions and strong corporate earnings.

Earnings estimates for Merck for 2025 have declined from $9.57 to $9.44 per share over the past 30 days. The healthcare bellwether’s performance has been solid, with the company exceeding ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks Jim Cramer recently discussed. In his latest appearance on CNBC's Squawk on the ...

Investors in Merck & Co Inc (Symbol: MRK) saw new options become available today, for the March 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRK ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks. Dividend stocks, while popular among investors, have been ...

Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed ... compensation program that limits pharma company liability. Kennedy has an arrangement ...

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, Merck, if confirmed. By Christina Jewett and Sheryl Gay Stolberg ...